Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Itraconazole and JNJ-42165279 in Healthy Males
NCT02065739Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JNJ-42165279 in anxiety disorders and major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 11, Time to Reach Maximum Observed Plasma Concentration at Day 11 and 5 more. Started Jan 2014; status: completed.
02
Drugs
JNJ-42165279
03
Conditions
anxiety disordersmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02065739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065739.